NZ764713B2 - A Bacteroides thetaiotaomicron strain and its use in reducing inflammation - Google Patents

Abstract

The present invention provides a strain of Bacteroides thetaiotaomicron and derivatives thereof, and the use of said strain or derivatives in treating inflammatory, autoimmune and allergic disorders. The invention also provides pharmaceutical compositions, nutritional supplements, feedstuffs, food products, dietary supplements, and food additives comprising said strain or derivatives. roducts, dietary supplements, and food additives comprising said strain or derivatives.

Description

A Bacteroides thetaiotaomicron strain and its use in reducing inflammation Related applications This application is a divisional application of New Zealand patent application no. 732667, a New Zealand national phase entry application derived from International Patent Application No. , filed on 22 December 2015, which claims the t of UK Patent Application No. 1423084.1, filed on 23 December 2014, the contents of each of which are incorporated herein in their entirety by nce.

Field of the Invention The present invention relates to microorganisms that are able to positively modulate matory disorders and which may be used in therapy or preventative medicine.

Background of the Invention Bacteroides thetaiotaomicron has potent anti-inflammatory effects in vitro and in vivo (Kelly et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclearcytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004 Jan;5(1):104-12). It modulates molecular signalling pathways of NF-κB (Kelly et al, Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol. 2004 Jan;5(1):104-12). In particular, it stops binding of the active ent (RelA) of NF-κB to key genes in the nucleus, thereby preventing the activation of pro-inflammatory pathways (Kelly et al, Supra 2004). The full genome of B. thetaiotaomicron was sequenced and annotated by the Gordon Group (Washington University School of ne, USA) in 2003 [Xu et al, A genomic view of the Bacteroides thetaiotaomicron symbiosis. e. 2003 Mar 28;299(5615):2074-6].

Summary of the Invention The present invention is based on the discovery of a strain of Bacteroides thetaiotaomicron (BT) that has surprising efficacy against inflammatory disorders. ingly the strain of BT is useful as a therapeutic or in preventative medicine against inflammatory disorders and/or autoimmune disorders and /or allergic ers. ing to one aspect, the present invention provides a composition comprising a Bacteroides thetaiotaomicron strain with a sequence that has at least 99.5% sequence identity to SEQ ID NO: 1, n said Bacteroides thetaiotaomicron strain has a comparable increase in the percentage of Treg cells in the small intestine lamina a tissue samples from Bacteroides otaomicron/DSS treated mice to that of oides thetaiotaomicron deposited as Accession Number 42341 at NCIMB, and wherein said Bacteroides thetaiotaomicron strain is not the Bacteroides thetaiotaomicron deposited as Accession Number 42341 at NCIMB.

According to another aspect, the present invention provides the use of the ition ing to the invention in the cture of a medicament for treating or preventing inflammatory disorders and/or autoimmune ers and/or allergic disorders in a subject.

According to another aspect, the present invention provides the use of the composition according to the invention in the manufacture of a medicament for reducing the inflammation of a tissue or an organ.

According to another aspect, the present invention es the use of the composition according to the invention in the cture of a medicament for reducing disruption to the colon of a subject.

According to another aspect, the present invention provides the use of the composition according to the invention in the cture of a medicament for reducing the sion of one or more pro-inflammatory genes in a cell or cells of a subject.

According to another aspect, the present invention provides the use of the composition according to the invention in the manufacture of a medicament for increasing the percentage of T regs in the alimentary canal or a section of the alimentary canal.

According to another aspect, the present invention es a process for producing a composition ing to the invention, said process comprising admixing said Bacteroides thetaiotaomicron strain with a pharmaceutically acceptable excipient, r or diluent.

According to another , the present invention provides a nutritional supplement, feedstuff, food product, dietary supplement or food additive comprising the composition according to the invention.

Also disclosed herein is a Bacteroides thetaiotaomicron deposited as NCIMB Accession Number 42341, or a derivative thereof.

Also disclosed herein is a ional supplement comprising a Bacteroides thetaiotaomicron as defined , and a nutritionally acceptable excipient, carrier or diluent.

Also disclosed herein is a feedstuff, food product, dietary supplement, or food additive comprising a Bacteroides thetaiotaomicron as defined herein.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a ition as defined herein, a pharmaceutical composition as d herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein, for use in modulating the inflammation of a tissue or an organ in a subject.

Also disclosed herein is a Bacteroides otaomicron as d herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein, for use in the treatment and/or prevention of a disorder in a subject; wherein said disorder is an inflammatory disorder and/or an autoimmune disorder.

Also disclosed herein is a Bacteroides thetaiotaomicron as d herein, a composition as d herein, a pharmaceutical composition as defined , a nutritional ment as defined herein or a feedstuff, a food product, a y supplement, or a food additive as defined herein for use in ng disruption to the colon of a subject, preferably said subject has IBD.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional ment as defined herein or a feedstuff, a food product, a dietary ment, or a food additive as defined herein for use in reducing the expression of one or more pro-inflammatory genes in a cell or cells of a subject.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food t, a dietary supplement, or a food additive as defined herein for use in increasing the percentage of regulatory T cells (Tregs) in the alimentary canal or a section of the alimentary canal.

Also disclosed herein is a process for producing a pharmaceutical composition described herein, said process comprising admixing said Bacteroides thetaiotaomicron with a pharmaceutically acceptable ent, carrier or diluent, wherein said Bacteroides otaomicron is optionally encapsulated in said process.

Also sed hereinis a method for modulating the inflammation of a tissue or an organ in a subject wherein said method comprises administering to the subject a Bacteroides thetaiotaomicron as defined herein, a composition as defined , a pharmaceutical composition as defined herein, a ional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein.

Also disclosed herein is a method for treating and/or preventing of an matory disorder and/or an autoimmune disorder in a subject wherein said method comprises administering to the subject a Bacteroides thetaiotaomicron as d , a ition as defined herein, a pharmaceutical composition as defined herein, a ional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein.

Also disclosed herein is a method for reducing disruption to the colon of a subject wherein said method comprises administering to the subject a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein , a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a uff, a food product, a dietary supplement, or a food additive as defined herein, preferably wherein the t has IBD.

Also disclosed herein is a method for reducing the expression of one or more pro-inflammatory genes in a cell or cells of a subject wherein said methodcomprises administering to the subject a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as d herein.

Also disclosed herein is a method for increasing the percentage of Regulatory T cells (Tregs) in the alimentary canal or a n of the alimentary canal wherein said method ses administering to the subject a Bacteroides thetaiotaomicron as d herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional ment as defined herein or a uff, a food product, a dietary supplement, or a food additive as defined herein.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a composition as d herein, a pharmaceutical composition as defined herein, a ional ment as defined herein or a uff, a food product, a dietary ment, or a food additive as defined herein, for the manufacture of a medicament for modulating the mation of a tissue or an organ in a subject.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional ment as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein, for the manufacture of a medicament for the treatment and/or prevention of an inflammatory disorder and/or an autoimmune disorder in a subject.

Also disclosed herein is a Bacteroides otaomicron as defined herein, a composition as d herein, a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein for the manufacture of a medicament for reducing disruption to the colon of a subject, preferably wherein the subject has IBD.

Also disclosed herein is a Bacteroides thetaiotaomicron as defined herein, a composition as defined herein, a pharmaceutical ition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein for the manufacture of a medicament for reducing the expression of one or more pro-inflammatory genes in a cell or cells of a subject.

Also sed herein is a Bacteroides thetaiotaomicron as defined , a composition as defined herein, a pharmaceutical composition as defined herein, a nutritional supplement as defined herein or a feedstuff, a food product, a dietary supplement, or a food additive as defined herein for the cture of a medicament for increasing the percentage of Regulatory T cells (Tregs) in the alimentary canal or a section of the alimentary canal.

Brief Description of the Figures The ion is described with nce to the accompanying figures, wherein: Figure 1 illustrates the attenuation of colitis via expansion of Treg cells with B. thetaiotaomicron strain BT2013 in a DSS induced colitis model.

Figure 2 illustrates that B. thetaiotaomicron strain BT2013 does not influence Treg cells, but influences Teff cells, in conventional mice; Figure 3: illustrates the myeloperoxidase (MPO) activity in ileum (a) and caecum (b) of mice dosed with DSS with or without a daily intake of B. thetaiotaomicron Figure 4: illustrates histopathology in ascending colon of female C57Bl/6 mice dosed with DSS (a) or DSS and B. thetaiotaomicron (b) Figure 5: illustrates the mean histopathological tissue scores for the ascending colon from mice colonised with B. thetaiotaomicron strains E1 and BT2013 during DSS-induced colitis; Figure 6: illustrates the expression of lammatory genes (IL-1β and IL-6) and antiinflammatory gene (IL-10) in the ascending colon of mice treated with B. otaomicron s E1, E2 and BT2013; Figure 7: illustrates the expression of IL-8 in Caco-2 cells incubated with PMA and medium or bacterial cells E1, E2 and BT2013.

Detailed ption of the Invention The present invention is based on the finding that BT strain BT2013 has more potent anti-inflammatory effects compared to l BT s.

BT strain BT2013 has been deposited under Accession number 42341 on 3 December 2014 at National Collections of Industrial, Food and Marine Bacteria (NCIMB) at NCIMB Ltd, Ferguson Building, Craibstone Estate, Bucksburn, [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM ation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM Aberdeen, UK, AB21 9YA. The t was made under the terms of the Budapest Treaty. The t was made by GT Biologics Ltd. (Life Sciences Innovation Building, en, AB25 2ZS, Scotland). GT Biologics Ltd. has subsequently changed its name to 4D Pharma Research Limited.

Derivative The present invention encompasses derivatives of the deposited strain.

The term “derivative” includes daughter strains (progeny) or stains cultured (sub- cloned) from the original but modified in some way (including at the genetic level), without ng negatively the biological activity, i.e. the derivative strain will have at least the same immune modulatory activity as the original BT2013 strain.

A genome ce for strain BT2013 is provided in SEQ ID NO:1.

Bacterial strains that are es of the bacterium deposited under accession number NCIMB 42341 are also expected to be effective for treating or preventing inflammatory disorders and/or autoimmune disorders and/or allergic disorders. A e is a y related strain that has the same or very similar physiological and biochemical characteristics.

In certain ments, the bacterial strain for use in the invention has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA ce of the bacterium deposited under accession number NCIMB 42341.

Alternatively, strains that are biotypes of the bacterium deposited under accession number NCIMB 42341 and that are suitable for use in the invention may be identified by sequencing other nucleotide sequences for the bacterium deposited under accession number NCIMB 42341. For example substantially the whole genome may be sequenced and a biotype strain for use in the invention may have at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity across at least 80% of its whole genome (e.g. across at least 85%, 90%, 95% or 99%, or across its whole genome). Other suitable sequences for use in identifying biotype strains may include hsp60 or repetitive sequences such as BOX, ERIC, dGTG)5, or REP ( Masco et al. (2003) Systematic and Applied Microbiology, 26:557-63). Biotype strains may have sequences with at least 95%, 96%, 97%, 98%, [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM ionNone set by KJM [Annotation] KJM Unmarked set by KJM 99%, 99.5% or 99.9% ce ty to the corresponding sequence of the bacterium ted under accession number NCIMB 42341.

In n embodiments, the bacterial strain for use in the invention has a genome with sequence identity to SEQ ID NO:1. In preferred embodiments, the bacterial strain for use in the invention has a genome with at least 90% sequence identity (e.g. at least 92%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) to SEQ ID NO:1 across at least 60% (e.g. at least 65%, 70%, 75%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100%) of SEQ ID NO:1. For example, the bacterial strain for use in the invention may have a genome with at least 90% ce identity to SEQ ID NO:1 across 70% of SEQ ID NO:1, or at least 90% sequence identity to SEQ ID NO:1 across 80% of SEQ ID NO:1, or at least 90% sequence identity to SEQ ID NO:1 across 90% of SEQ ID NO:1, or at least 90% ce identity to SEQ ID NO:1 across 100% of SEQ ID NO:1, or at least 95% sequence identity to SEQ ID NO:1 across 70% of SEQ ID NO:1, or at least 95% sequence identity to SEQ ID NO:1 across 80% of SEQ ID NO:1, or at least 95% sequence ty to SEQ ID NO:1 across 90% of SEQ ID NO:1, or at least 95% sequence identity to SEQ ID NO:1 across 100% of SEQ ID NO:1, or at least 98% sequence identity to SEQ ID NO:1 across 70% of SEQ ID NO:1, or at least 98% sequence identity to SEQ ID NO:1 across 80% of SEQ ID NO:1, or at least 98% sequence identity to SEQ ID NO:1 across 90% of SEQ ID NO:1, or at least 98% sequence identity to SEQ ID NO:1 across 100% of SEQ ID NO:1.

Alternatively, strains that are biotypes of the bacterium deposited under accession number NCIMB 42341 and that are suitable for use in the invention may be identified by using the accession number NCIMB 42341 deposit and restriction fragment is and/or PCR analysis, for example by using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprinting, or protein profiling, or partial 168 or 23s rDNA sequencing.

In certain embodiments, strains that are biotypes of the bacterium deposited under accession number NCIMB 42341 and that are suitable for use in the invention are strains that provide the same pattern as the bacterium deposited under accession number NCIMB 42341 when analysed by amplified ribosomal dNA restriction analysis (ARDRA), for example when using Sau3Al ction nzyme (for exemplary methods and guidance see, for example, Srutkova et al.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM ionNone set by KJM [Annotation] KJM ed set by KJM (2011) J. Microbiol. Methods, 87(1):10-6). Alternatively, biotype strains are identified as strains that have the same carbohydrate fermentation patterns as the bacterium deposited under accession number NCIMB 42341.

Bacterial strains that are biotypes of the bacterium deposited under accession number NCIMB 42341 and that are useful in the compositions and methods of the invention may be identified using any appropriate method or strategy. For example, bacterial strains that have similar growth patterns, metabolic type and/or surface ns to the bacterium deposited under accession number NCIMB 42341 may be useful in the invention. A biotype strain will have comparable immune modulatory ty to the NCIMB 42341 . For example, a biotype strain will elicit comparable effects on the DSS-induced colitis models and comparable effects on Treg levels, MPO enzymatic activity, inflammation-associated gene expression and colon histopathology to the effects shown in the Functional Assays, which may be identified by using the protocols described in the Functional Assays.

Disorders The Bacteroides thetaiotaomicron strain BT2013 may be used for the ent and/or prevention of a disorder in a subject, wherein said disorder is an inflammatory disorder and/or an autoimmune disorder.

In one embodiment, the disorder s the alimentary canal, a section of the alimentary canal, the liver, liver cells, immune cells, epithelial cells, epidermal cells, neuronal cells, endothelial cells, fibroblasts, the pancreas, and/or pancreatic cells (such as the islets of Langerhans).

Examples of sections (i.e. parts) of the tary canal include the oesophagus, the stomach and the intestine (such as the small intestine (e.g. the duodenum, the jejunum and the ileum) and/or the large ine (e.g. the caecum, ascending colon, transverse colon, descending colon, and sigmoid colon)).

Examples of lial cells include intestinal lial cells. Examples of immune cells include dendritic cells, monocytes/macrophages, Tcells and neutrophils.

In one embodiment, the er is selected from the group consisting of: [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM 1. Organ associated ers such as irritable bowel syndrome (IBS), inflammatory bowel e including Crohn’s disease and ulcerative colitis, necrotising enterocolitis, pouchitis, coeliac disease, multiple sclerosis (brain), type I diabetes, Goodpasture’s me, Hashimoto ditis, chronic active hepatitis, cardiomyopathy, uveitis and rhinitis. 2. Systemic disorders such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, psoriasis, atopic itis, vitiligo, multiple sclerosis, alopecia areata, sarcoidosis, polymyositis and combinations thereof.

In one aspect, the disorder affects the intestine.

In one aspect, the disorder is an inflammatory disorder. For example, the disorder is an inflammatory bowel disorder (IBD) such as Crohn’s e.

In one aspect, the er is an autoimmune disorder. For example, the autoimmune disorder is selected from the group consisting of ulcerative colitis, pouchitis, rheumatoid arthritis, psoriasis, multiple sclerosis, type I diabetes, allergies (including coeliac disease), atopic dermatitis and rhinitis.

Subject In one embodiment, the subject is a monogastric animal.

Examples of monogastric animals e poultry, humans, rats, pigs, dogs, cats, horses and rabbits.

In another embodiment, the subject is a mammal such as a monogastric mammal.

Examples of monogastric mammals include omnivores (such as humans, rats, and pigs), carnivores (such as dogs and cats), and herbivores (such as horses and rabbits).

Preferably, the t is a human.

In one , the subject has a disorder is selected from the group consisting of inflammatory bowel disorder (IBD), s, rheumatoid arthritis, psoriasis, multiple sclerosis, type I diabetes, coeliac disease, atopic dermatitis, is, irritable bowel syndrome (IBS), ulcerative colitis, pouchitis, Crohn's e, functional dyspepsia, atopic diseases, necrotising enterocolitis, non alcoholic fatty liver disease, gastrointestinal infection and combinations thereof. dor e, the subject has IBD.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM ed set by KJM Modulation/regulation The terms “modulation” and “regulation” may be used interchangeably herein.

In one embodiment The B. thetaiotaomicron strain BT2013 is used to modulate the inflammation of a cell, a tissue or an organ in a subject.

In one embodiment, the term “modulation” refers to an increase and/or induction and/or ion and/or activation. In an alternative embodiment, the term “modulation” refers to a decrease and/or reduction and/or inhibition.

In one embodiment, the term “regulation” refers to an upregulation. In an alternative embodiment, the term “regulation” refers to a downregulation.

In one ment, the B. thetaiotaomicron strain BT2013 as bed herein reduces the inflammation of a cell, a tissue or an organ. For example, inflammation of the alimentary canal, a section (i.e. part) of the alimentary canal (such as the intestine), the liver, liver cells, epithelial cells, epidermal cells, neuronal cells, elial cells, fibroblasts, the pancreas, and/or atic cells (such as the islets of Langerhans) is reduced.

In one e, inflammation of the alimentary canal or part thereof (such as the intestine) is reduced.

In another example, inflammation by immune cells of the tissue or the organ is d.

In another example, inflammation by epithelial cells of the tissue or the organ is reduced.

The term “inflammation” as used herein refers to one or more of the following: redness, swelling, pain, tenderness, heat, and disturbed function of a cell, a tissue or organ due to an inflammatory s triggered by over-reaction of the immune system.

In one embodiment, the numbers of cells which are inflamed in a subject is at least 10%, 20%, 30%, 40% or 50% lower after administration of the polypeptide or polynucleotide or host cell as described herein when compared to the numbers of cells which are inflamed in a subject before the strain BT2013 as described herein is administered to the t.

In one embodiment, the amount of a tissue or organ which is inflamed in a dubject is at least 10%, 20%, 30%, 40% or 50% lower after administration of strain [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM ation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM BT2013 when compared to the amount of tissue or organ which is inflamed in a subject before the strain BT2013 is stered to the subject.

In one embodiment, the strain BT2013 reduces the inflammation by epithelial cells of the tissue or the organ.

For example, the lial cells are epithelial cells of the alimentary canal or part thereof (such as the intestine).

Without wishing to be bound by theory, the strain BT2013 increases the production of T cells (such as regulatory T cells which may also be referred to as Tregs) in a subject. This increase in Treg numbers may combat the effects of other effector T cells (also referred to as Teffs), such as Th1, Th1? and Th2 which drive inflammation, autoimmunity and allergic/atopic conditions. In Crohn’s disease and ulcerative s the Teff/Treg cell balance is lost.

In one embodiment, the production ofT cells in a t is increased such that there are at least 10%, 20%, 30%, 40% or 50% more T cells, or greater than 100% more T cells after administration of the polypeptide or polynucleotide or host cell as described herein when compared to the number of T cells in the subject before the strain BT2013 is administered to the subject.

Intestine r integrity In one embodiment, the strain BT2013 is used to e intestine r integrity in a subject.

The term “improving intestine barrier integrity” as used herein refers to a reduction in the numbers and/or types of rganisms which spread from the intestine into other cells in a subject after administration of the strain BT2013 when compared to the numbers and/or types of microorganisms which spread from the intestine into other cells in a subject before administration of the strain BT2013 as described herein.

In one embodiment, the numbers of rganisms which spread from the intestine into other cells in a subject are at least 10%, 20%, 30%, 40% or 50% lower after administration of the strain BT2013 when compared to the numbers of microorganisms which spread from the intestine into other cells in a subject administration.

In one embodiment, there are at least 5%, 10%, 15% or 20% fewer types f microorganisms which spread from the intestine into other cells in a subject [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM ation] KJM Unmarked set by KJM after administration of the strain BT2013 when compared to the types of microorganisms which spread from the intestine into other cells in a subject before the administration.

Intestine disruption In one embodiment strain , is used to reduce disruption to the intestine (e.g. large ine) of a subject (such as a subject with IBD).

The term “disruption to the intestine of a subject” as used herein refers to an affect on the integrity of the mucosal epithelium and/or an affect on the number of goblet cells in the epithelium and/or an affect on the number of immune cells infiltrating the lamina a.

In one embodiment, strain BT2013 reduces or prevents disruption to the integrity of the mucosal epithelium and/or reduces or prevents a reduction in the number of goblet cells in the epithelium and/or reduces or prevents the infiltration of immune cells into the lamina propria.

In one embodiment, a reduction in tion to the integrity of the mucosal epithelium is a ion of at least 5%, 10%, 15% or 20% in the numbers of bacteria crossing from the intestinal lumen into intestinal cells after administration of strain BT2013 when compared to the numbers of bacteria crossing from the intestinal lumen into intestinal cells in a subject before administration.

In one embodiment, a reduction in the number of goblet cells in the epithelium is a reduction of at least 2%, 5%, 10%, 15% or 20% in the numbers of goblet cells in the lium of a subject after administration of strain BT2013 when ed to the number of goblet cells in the epithelium of a subject before administration.

In one embodiment, the reduction in the infiltration of immune cells into the lamina propria is such that over a fixed time period (such as 24 hours) there is a reduction of at least 5%, 10%, 15%, 20% or 30% in the numbers of immune cells (e.g. T cells) crossing into lamina propria cells after administration of strain BT2013 when compared to the numbers of immune cells (e.g. T cells) ng into the lamina propria in a subject before administration.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM Pro-inflammatory genes and barrier integrity genes In one embodiment, strain BT2013 is used to regulate the expression of one or more pro-inflammatory genes and/or one or more barrier integrity genes in a cell or cells of a subject.

In one embodiment, the term “regulate” refers to an upregulation in the expression of one or more pro-inflammatory genes. In an alternative embodiment, the term “regulate” refers to a downregulation in the expression of one or more flammatory genes.

In one embodiment, strain BT2013 gulates the expression of one or more pro-inflammatory genes in a cell or cells of a subject.

The term “pro-inflammatory gene” as used herein refers to a gene which, when expressed, promotes inflammation. Examples of pro-inflammatory genes e genes encoding but notlimited to IL1-B, IL4, IL5, IL6, IL8, IL12, IL13, IL17, IL21, IL22, IL23, IL27, IFN, CCL2, CCL3, CCL5, CCL20, CXCL5, CXCL10, CXCL12, CXCL13, and TNF-oc.

In one embodiment, the pro-inflammatory gene is selected from the group consisting of IL1-B, IL6 and IL8.

In one ment, the expression level (eg. mRNA level) of one or more pro-inflammatory genes is decreased (i.e. downregulated) such that the level is at least 10%, 20%, 30%, 40% or 50% lower after administration of the strain BT2013 when compared to the level in the subject before administration.

The term “barrier integrity genes” as used herein refers to a gene which, when expressed, has a role in the function of the barrier of the intestine such as the repair of the barrier and the prevention of microorganisms crossing the barrier. es of barrier ity genes include genes encoding Retnlg|Retnlb, Si, Defa24, Hsd11b2, Hsd17b2, and Thra.

In one ment, the term “regulate” refers to an upregulation in the expression of one or more barrier integrity genes. In an alternative embodiment, the term “regulate” refers to a downregulation in the expression of one or more barrier integrity genes.

In one ment, strain BT2013 upregulates the expression of barrier ity genes in a cell or cells of a subject In one embodiment, the barrier integrity gene is selected from the group gonsisting of Retnlg|Retnlb, Si, Defa24, Hsd11b2, Hsd17b2, and Nr1d1|Thra.

[Annotation] KJM None set by KJM [Annotation] KJM ionNone set by KJM ation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM In one embodiment, the expression level (e.g. mRNA level) of one or more barrier integrity genes is sed (i.e. upregulated) such that the level is at least %, 20%, 30%, 40% or 50% higher after administration of strain BT2013 when compared to the level in the subject before administration.

Alimentary canal Parts of the alimentary canal e the oesophagus, the stomach and the intestine (such as the small intestine (e.g. the duodenum, the jejunum and the ileum) and/or the large intestine (e.g. the caecum, ascending colon, transverse colon, descending colon, and sigmoid ).

Herein, the term “large intestine” may be used interchangeably with the term “colon”.

In one embodiment, strain BT2013 is used for improving alimentary canal health in a subject.

The term ving alimentary canal health” as used herein refers to reducing the level of inflammation in the alimentary canal or part thereof and/or improving intestinal microbiota.

In one ment, the level of mation in the alimentary canal is at least 10%, 20%, 30%, 40% or 50% lower after administration of strain BT2013 when compared to the level of inflammation in the alimentary canal of a subject before administration.

In one embodiment, strain BT2013 is used for improving intestinal microbiota in a subject.

The term “intestinal microbiota” as used herein refers to microorganisms that live in the digestive tract of the host animals. These microorganisms perform a wide variety of metabolic, structural, protective and other beneficiary functions.

As used herein, the term “improving intestinal microbiota” refers to increasing the number and/or type of desirable rganisms present in the intestine of a subject (e.g. the host), and/or increasing the activity of said desirable microorganisms in terms of their metabolic, structural, protective and other beneficiary functions. The term “improving intestinal iota” may also refer to decreasing the number and/or type of undesirable microorganisms present in the intestine of a subject (e.g. the host), and/or decreasing the activity of said [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM undesirable microorganisms in terms of their metabolic, structural, protective and other beneficiary functions.

Microorganisms which are desirable in the intestine of a host are those rganisms which have a protective and beneficiary function. Firmicutes and bacteroidetes bacteria are examples of desirable microorganisms in the intestine of a host.

Microorganisms which are undesirable in the intestine of a host are those microorganisms which can interfere with the metabolic, structural, protective and other beneficiary functions of desirable microorganisms in the intestine have a protective and beneficiary function. In addition or alternatively, undesirable microorganisms are those which cause, for example, mation and/or diarrhoea. E. coli is an example of an undesirable microorganism in the intestine of a host.

For example, a change in the microbiota balance between desirable microorganism (such as firmicutes and bacteroidetes bacteria) and undesirable microorganisms (such as E.co/i: ETEC, EPEC, EIEC, EHEC and EAEC) within the intestine may occur in subjects with matory bowel disease (IBD) once strain BT2013 has been administered to the subject.

In one embodiment, the number of desirable microorganisms (such as firmicutes and bacteroidetes ia) present in the intestine of a subject (e.g. the host), is increased such that the number of microorganisms is at least 10%, %, 30%, 40% or 50% higher, or greater than 100% higher after administration of the strain BT2013 compared to the level in the subject before administration.

In addition, or atively, the types of desirable microorganisms (such as utes and bacteroidetes) t in the intestine of a subject (e.g. the host), are increased such that there are at least 2%, 5%, 10%, or 15% more types of microorganisms after stration of strain BT2013 when compared to the types in the subject before stration.

In one embodiment, the number of undesirable microorganisms (such as E. coli ETEC, EPEC, EIEC, EHEC and EAEC) present in the intestine ofa subject (e.g. the host), is decreased such that the number of microorganisms is at least %, 20%, 30%, 40% or 50% lower after administration strain BT2013 when dompared to the level in the subject before administration. In addition, or lternatively, the types of rable microorganisms (such as E. coli ETEC, [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM EPEC, EIEC, EHEC and EAEC) present in the intestine ofa subject (e.g. the host), are decreased such that there are at least 1%, 2%, 5%, or 10%, fewer types of undesirable microorganisms after administration of strain BT2013 when compared to the types in the subject before administration.

Encapsulation In one embodiment, the B. thetaiotaomicron strain BT2013 is encapsulated.

In a further embodiment, a pharmaceutical composition sing the strain BT2013 is encapsulated.

In another embodiment, a nutritional supplement comprising the strain BT2013 is encapsulated.

In a further embodiment, a feedstuff, food product, dietary supplement, or food additive as described herein is encapsulated.

The term “encapsulated” as used herein refers to a means for protecting the strain BT2013 from an atible environment by physical separation so that it can be delivered to the target site (e.g. the intestine) without degradation or significant degradation in order that the strain BT2013 can have an effect on the target site. An example is an enteric coated e or an enterically-resistant capsule.

Even when the objective of the encapsulation is the isolation of the strain from its ndings, the protective coating or shell must be ruptured at the time of desired action. The rupturing of the protective coating or shell is typically t about through the application of chemical and al stimuli such as pressure, enzyme attack, chemical on and al disintegration.

For example, encapsulation ensures that the strain can be ingested so that the microorganisms can be delivered to the target site (e.g. the intestine) in an amount which is ive to produce an effect at the target site.

Pharmaceutical composition In one embodiment, a pharmaceutical composition comprises microorganisms of the strain BT2013 and optionally a pharmaceutically dcceptable excipient, carrier or diluent.

[Annotation] KJM None set by KJM ation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM The pharmaceutical composition may be any pharmaceutical composition.

In one aspect, the pharmaceutical composition is to be administered orally, enterally or rectally. For example, the composition may be an edible composition.

"Edible" means a material that is approved for human or animal consumption.

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine.

Examples of such suitable excipients for the various different forms of ceutical compositions described herein may be found in the “Handbook of Pharmaceutical Excipients, 2nd Edition, (1994), Edited by AWade and PJ Weller.

Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. o edit. 1985).

Examples of le carriers e lactose, starch, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol and the like.

Examples of suitable diluents include one or more of: water, ethanol, glycerol, propylene glycol and glycerin, and ations thereof.

The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and rd pharmaceutical practice. The pharmaceutical compositions may comprise as, or in addition to, the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

Examples of suitable binders e starch, n, natural sugars such as glucose, anhydrous lactose, free-flow lactose, beta-lactose, corn sweeteners, natural and tic gums, such as acacia, tragacanth or sodium alginate, carboxymethyl cellulose and polyethylene glycol.

Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium te, sodium e, sodium de and the like.

Preservatives, stabilizers, dyes and even flavouring agents may be provided in the pharmaceutical ition. Examples of preservatives include sodium te, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

In one aspect, the microorganisms of strain BT2013 pharmaceutical nomposition are encapsulated.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM The pharmaceutical may be in the form of a solution or as a solid — depending on the use and/or the mode of ation and/or the mode of administration.

As used herein, the term "medicament" encompasses medicaments for both human and animal usage in human and veterinary medicine. In addition, the term ament" as used herein means any substance, which es a therapeutic and/or beneficial effect. The term "medicament" as used herein is not necessarily limited to substances, which need Marketing Approval, but may include substances which, can be used in cosmetics, nutraceuticals, food ding feeds and beverages for example), probiotic cultures, nutritional supplements and natural remedies. In addition, the term "medicament" as used herein encompasses a product designed for incorporation in animal feed, for example ock feed and/or pet food.

Nutritional supplements Nutritionally acceptable rs, diluents and excipients e those suitable for human or animal consumption and that are used as standard in the food industry. Typical nutritionally acceptable carriers, ts and ents will be familiar to the skilled person in the art.

In one embodiment, a nutritional supplement comprises microorganisms of strain BT2013 or a host cell comprising an expression vector comprising said polynucleotide sequence, and a nutritional acceptable excipient, carrier or diluent.

In one example, the microorganisms of strain BT2013 are ulated.

Feedstufflproducts A further aspect of the invention s to feedstuffs, food products, dietary supplements and food additives comprising microorganisms of strain BT2013.

The terms “feedstuff”, "food t" “food additive” and “dietary supplement” as used herein are intended to cover all consumable products that can be solid, jellied or liquid.

The term “food product” is used in a broad sense — and covers food for humans as well as food for animals (i.e. a feed). In one aspect, the food product a: for human consumption. Examples of food products include diary products uch as milk, cheese, beverages comprising whey protein, milk drinks, lactic acid [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM bacteria drinks, yoghurt, ng yoghurt), bakery products, beverages and beverage powders.

The “feedstuff”, "food product" “food additive” and “dietary supplement” may be in the form of a solution or as a solid — depending on the use and/or the mode of application and/or the mode of administration.

As used herein the term “dietary supplement” includes a formulation which is or can be added to a food product or feedstuff as a nutritional supplement. The term “dietary supplement” as used here also refers to ations which can be used at low levels in a wide variety of products that require gelling, texturising, stabilising, suspending, film-forming and structuring, retention of juiciness and improved mouthfeel, without adding viscosity.

Suitable food ts may e, for example, functional food products, food compositions, pet food, livestock feed, health foods, feedstuffs and the like.

In one aspect, the food product is a health food.

As used herein, the term ional food product" means food that is capable of providing not only a ional effect, but is also capable of delivering a further beneficial effect to the consumer. Accordingly, functional foods are ordinary foods that have components or ingredients (such as those described ) orated into them that impart to the food a ic functional - e.g. medical or physiological benefit - other than a purely nutritional effect.

Examples of specific food products that are applicable to the present invention include milk-based products, ready to eat desserts, powders for re- constitution with, e.g., milk or water, chocolate milk , malt drinks, ready-to- eat dishes, instant dishes or drinks for humans or food compositions representing a complete or a partial diet intended for pets or livestock.

In one aspect, the feedstuff, food product, dietary supplement or food additive according to the present invention are intended for humans, pets or livestock such as monogastric animals. The feedstuff, food product, dietary supplement or food additive may be intended for s selected from the group consisting of dogs, cats, pigs, horses, or y. In a r embodiment, the food product, dietary supplement or food additive is intended for adult species, in particular human adults.

The term based product" as used herein means any liquid or semi- QOlid milk or whey based product having a varying fat content. The milk-based ation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM ation] KJM Unmarked set by KJM ation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM product can be, e.g., cow's milk, goat's milk, sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk and whey without any processing, or a processed product, such as yoghurt, d milk, curd, sour milk, sour whole milk, butter milk and other sour milk products. Another important group includes milk beverages, such as whey beverages, fermented milks, condensed milks, infant or baby milks; flavoured milks, ice cream; milk-containing food such as sweets.

The uffs, food ts, dietary supplements or food additives of the present invention may be - or may be added to - food supplements, also referred to herein as dietary or nutritional supplements or food additives.

The feedstuffs, food products, dietary ments or food ves according to the ion may also be used in animal nutrition (e.g. in pig nutrition), particularly in the early-weaned period and growing fattening period.

The feedstuffs, food products, dietary supplements orfood additives are expected to enhance immune function reduce and prevent infectious diseases, beneficially alterthe microbiota composition, and improve growth and performance of animals, for example, through increased feed conversion efficiency.

In one embodiment the feedstuff, food product, dietary supplement, orfood additive is encapsulated.

Live biotherapeutic product The microorganisms of strain BT2013 may be used in or as a live biotherapeutic product (LBP).

In one aspect, the LBP is an orally administrable composition of metabolically active, i.e., live and/or lyophilized, or able heat-killed, irradiated or lysed bacteria. The LBP may contain other ingredients. The LBP can be administered orally, i.e., in the form of a tablet, capsule or . The LBP may additionally comprise other bacterial species, for example, the bacterial species R. hominis. ulated products are favoured for R. hominis as it is an anaerobe. Other ients (such as vitamin C, for example), may be included as oxygen scavengers and substrates (such as these improve the colonisation and survival in vivo). Alternatively, the LBP of the invention may be administered orally as a food or nutritional product, such as milk or whey based ted dairy droduct, or as a pharmaceutical product.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM ed set by KJM [Annotation] KJM None set by KJM ation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM A le daily dose of the bacteria in the LBP is from about 1 x 103 to about 1 x 1012 colony forming units (CFU); for example, from about 1 x 107 to about 1 x1010 CFU; in another example from about 1 x 106 to about 1 FU.

In one aspect, the LBP contains the bacterial species and/or cellular components thereof, as active ingredients, in an amount of from about 1 x 106 to about 1 x 1012 CFU/g, respect to the weight of the composition; for example, from about 1 x 108 to about 1 x 1010 CFU/g. Typically, a LBP is optionally combined with at least one suitable prebiotic compound. A prebiotic is usually a non- digestible carbohydrate such as an oligo- or polysaccharide, or a sugar alcohol, which is not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and alacto-oligosaccharides.

In one aspect, the LBP of the present description includes a tic in an amount of from about 1 to about 30% by weight, respect to the total weight composition, (e.g. from 5 to 20% by weight). Carbohydrates may be selected from the group consisting of: fructo- oligosaccharides (or FOS), short-chain fructo- oligosaccharides, inulin, isomalt-oligosaccharides, pectins, xylo-oligosaccharides (or XOS), chitosan-oligosaccharides (or COS), beta-glucans, arable gum modified and resistant starches, polydextrose, tose, acacia fibers, carob, oats, and citrus fibers. In one aspect, the prebiotics are the short-chain fructo- oligosaccharides (for city shown hereinbelow as FOSs-cc); said FOSs-cc. are not digestible carbohydrates, lly ed by the conversion of the beet sugar and including a saccharose molecule to which three glucose molecules are bonded.

Administration The pharmaceutical compositions, the nutritional supplements, feedstuffs, food products, dietary ments or food additives of the present invention may be adapted for oral, rectal, vaginal, parenteral, intramuscular, intraperitoneal, intraarterial, intrathecal, intrabronchial, aneous, intradermal, intravenous, nasal, buccal or sublingual routes of administration.

In one aspect, the pharmaceutical compositions, the nutritional supplements, feedstuffs, food products, dietary ments or food additives of de present invention are adapted for oral, rectal, l, parenteral, nasal, buccalr sublingual routes of administration. ation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM In a further aspect, the pharmaceutical compositions, the nutritional supplements, feedstuffs, food products, dietary supplements or food additives of the present invention are adapted for oral administration.

For oral administration, particular use is made of compressed tablets, pills, tablets, gellules, drops, and es.

Other forms of administration se solutions or emulsions which may be injected intravenously, rterially, intrathecally, subcutaneously, ermally, intraperitoneally or intramuscularly, and which are prepared from sterile or sterilisable solutions. The pharmaceutical compositions of the present invention may also be in form of itories, pessaries and suspensions.

Pharmaceutical compositions, the nutritional supplements, feedstuffs, food products, dietary supplements or food additives may be formulated in unit dosage form, i.e., in the form of discrete portions containing a unit dose, or a multiple or sub-unit of a unit dose.

Dosage A person of ordinary skill in the art can easily determine an appropriate dosage amount of the strain BT2013 to administer to a subject without undue experimentation. Typically, a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the strain employed, the lic stability and length of action of that strain, the age, body , general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the dual undergoing therapy. The dosages disclosed herein are ary of the average case. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Combinations In one aspect, microorganisms of strain BT2013 are administered in combination with one or more other active agents. In such cases, the microorganisms of strain BT2013 may be stered utively, dimultaneously or sequentially with the one or more other active agents.

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM Functional Assays: In Vivo Model C57BL/6 mice (6 weeks old) were used to evaluate the therapeutic effect of B. thetaiotaomicron strains E1, E2 and BT2013 during DSS-induced colitis. The mice were colonised with one of the B. thetaiotaomicron strains prior to treatment with DSS. The animals were euthanized and intestinal tissue sampling was performed. Small intestine was collected for immunological analysis by flow cytometry and enzymatic activity measurements of the enzyme myeloperoxidase (MPO). Ascending colon were divided into equal parts and transferred to neutral buffered formalin (NBF; Sigma-Aldrich) for histological analysis or RNAIater (Ambion) for molecular analysis..

Flow cytometry analysis of T cell populations in small intestine lamina propria was carried out (figure 1 and figure 2). D88 alone and B. thetaiotaomicron treatment did not affect the total percentage of the CD3+CD4+CD8— population.

The populations influenced by DSS alone and B. otaomicron were the Tregs (CD25+FoxP3+* and FR4'“CD25+*) and Teff cells (FR4'°CD25+*) (figure 1 and 2).

The tage of Tregs was increased in mice treated with B. thetaiotaomicron strain BT2013 compared to DSS alone. The strain E1W did not appear to have any effect on Tregs. (figure 1). The effects of BT2013 in Tregs were only apparent in mice co-treatment with DSS. The strain had no effect on Tregs in untreated mice but did influence the Teff cell tion (figure 2).

The enzymatic activity of MPO in the ileum and caecum was determined (Figure 3 a and 3b). MP0 is a proinflammatory enzyme stored in the azurophilic granules of philic granulocytes. MP0 is used as an indicator of inflammation, specifically neutrophil recruitment and accumulation. The lower levels of MPO activity detected in i|ea| or caecal tissue samples from the B. thetaiotaomicron/D88 treated mice ed to DSS alone indicates a reduction in phil recruitment and ore a reduction in inflammation.

Histological is of ascending colon was carried out (Figures 4 and 5 and Table 1). The histopathology grading scheme was based on the ia of Berg et al 1996, as summarised: O = Shallow crypts, no or few rating inflammatory cells, intact lium, goblet cells appearfull of mucin. ie no pathology D 1 = Crypts may exhibit slight epithelial cell hyperplasia, some diffuse [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM infiltrating inflammatory cells may be seen between crypts, luminal epithelium appears intact, goblet cells may appear slightly depleted of mucin. 2 = Crypts appear deeper with ct evidence of epithelial hyperplasia, depletion of mucin from goblet cells, infiltrating inflammatory cells evident may be multifocal in nature ,though the infiltrates are not seen in the submucosa. 3 = Lesions involved a larger area of the mucosa and /or were more frequent than that seen in grade 2. The lesions did not e the submucosa.

The luminal epithelial cells exhibited small erosions. The lesions are not transmural. 4 = Crypt lium appears eroded. ses may be present.

Luminal epithelial cells appear irregular, sometimes with complete loss.

Transmural infiltrate is observed - this was often associated with complete loss of epithelial cells into the lumen.

The disruption to the colon as a result of DSS induced colitis was significantly reduced by treatment of mice with B. thetaiotaomicron strains E1, E2 and BT2013. The expression of inflammation—associated genes in the ascending colon was reduced in mice colonised with B. thetaiotaomicron compared to mice treated with DSS alone. The strains E1 and BT2013 greatly reduced lL1B and lL6 inflammatory gene expression compared to strain E2. (Figure 6) Table 1 TTEST L BT E1 BT 2013 BT E2 DSS 0.000 0.032 0.041 0.089 In Vitro Model The expression of the matory gene interleukin-8 induced in inal pithelial cells after PMA exposure was modulated in the presence of B. aomicron strains E1, E2 and BT2013 (Figure 7).

[Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM ed set by KJM [Annotation] KJM None set by KJM [Annotation] KJM MigrationNone set by KJM [Annotation] KJM Unmarked set by KJM Sequencing of strain BT2013 genome A DNA sample from strain BT2013 was subjected to sequencing on MiSeq (v2 nano 2x250bp) using a Nextera XT library for fast fragmentation and tagging with sequencing adaptors, to give a total of 4605120 reads (1115615927 bases).

The data analysis is ised below: a. Mapping to reference sequence (NC_004663 and NC_004703) using bowtie2 (2.2.2) b. SNV and small lnDel calling using VarScan (2.3.7) and SNVer (0.5.3) performing a sus call to avoid false positives c. Annotation of variations using reference gff d. Large lnDel calling using pindel (0.2.5a3) e. De-novo assembly of unmapped reads using SOAPdenovo (2.04) f. Blast of assembled contigs against NCBI nt database g. Subsampling of all reads of the sample to 50% h. De-novo assembly on the pled reads using SOAPdenovo (2.04) The sequences were mapped to the reference sequence (NC_004663 and NC_004703) using 2 (2.2.2). tide variations and small insertions and/or ons were identified using VarScan (2.3.7) and SNVer (0.5.3) to avoid false positives during sequencing and variations were annotated using a reference sequence. Large insertions and deletions were identified using pindel a3). Unmapped reads were assembled de novo using SOAPdenovo (2.04). The cing fragments were reassembled into contigs which were blasted against the NCBI nucleotide database. All the reads of the sample were subsampled to 50% and were then assembled de novo using SOAPdenovo (2.04) to provide_a concatenated version of the de novo ce assembly of BT2013.

Sequences SEQ ID NO:1 (concatenated version of the de novo sequence ly of BT2013) — see electronic sequence listing.

Claims (20)

Claims

1. A ition comprising a oides thetaiotaomicron strain with a sequence that has at least 99.5% sequence identity to SEQ ID NO: 1, wherein said Bacteroides thetaiotaomicron strain has a comparable increase in the percentage of Treg cells in small intestine lamina propria tissue samples from Bacteroides thetaiotaomicron/DSS treated mice to that of oides thetaiotaomicron deposited as Accession Number 42341 at NCIMB, and wherein said Bacteroides thetaiotaomicron strain is not the Bacteroides thetaiotaomicron ted as ion Number 42341 at NCIMB.

2. The composition according to claim 1, wherein said Bacteroides thetaiotaomicron 5 strain is encapsulated.

3. The composition according to claim 1 or claim 2, wherein the composition is a pharmaceutical composition r sing a pharmaceutically acceptable excipient, carrier or diluent.

4. Use of the composition according to any one of claims 1-3 in the manufacture of a medicament for treating or preventing inflammatory disorders and/or autoimmune disorders and/or allergic disorders in a subject. 15

5. The use ing to claim 4, wherein said disorder affects the alimentary canal, a section of the alimentary canal, and/or epithelial cells.

6. The use according to claim 4 or claim 5, wherein said disorder is selected from the group consisting of inflammatory bowel disorder (IBD), colitis, rheumatoid arthritis, 20 psoriasis, multiple sclerosis, type I diabetes, c disease, atopic dermatitis, rhinitis, ble bowel syndrome (IBS), tive colitis, pouchitis, Crohn's disease, functional dyspepsia, atopic diseases, necrotising enterocolitis, non-alcoholic fatty liver disease, gastrointestinal infection and combinations thereof. 25

7. Use of the composition according to any one of claims 1-3 in the manufacture of a medicament for reducing the mation of a tissue or an organ.

8. The use according to claim 7, wherein said Bacteroides thetaiotaomicron strain reduces the inflammation by epithelial cells of the tissue or the organ.

9. The use according to claim 8, wherein said epithelial cells are lial cells of the alimentary canal.

10. Use of the composition according to any one of claims 1-3 in the manufacture of a 35 medicament for reducing disruption to the colon of a subject.

11. The use according to claim 10, wherein said subject has IBD.

12. The use according to claim 10 or claim 11, n said Bacteroides thetaiotaomicron strain: a) reduces or prevents disruption to the integrity of the mucosal epithelium; 5 b) reduces or prevents a ion in the number of goblet cells in the epithelium; and/or c) reduces or prevents the infiltration of immune cells into the lamina propria.

13. Use of the composition according to any one of claims 1-3 in the manufacture of a 10 medicament for reducing the expression of one or more pro-inflammatory genes in a cell or cells of a subject.

14. The use according to claim 13, wherein said one or more pro-inflammatory genes is ed from the group consisting of IL1-β, IL6, IL8, IL10 and combinations thereof.

15. The use according to claim 13 or claim 14, wherein said cell is an alimentary canal cell (such as a cell of the ascending colon), or an epithelial cell (such as an intestinal epithelial cell). 20

16. Use of the composition according to any one of claims 1-3 in the manufacture of a medicament for increasing the percentage of T regs in the tary canal or a section of the alimentary canal.

17. The use according to claim 16, wherein said section of the alimentary canal is the 25 small intestine lamina propria.

18. A process for producing a composition according to claim 2, said process comprising ng said Bacteroides thetaiotaomicron strain with a pharmaceutically acceptable excipient, carrier or diluent.

19. The process according to claim 18, wherein said Bacteroides thetaiotaomicron strain is encapsulated in said process.

20. A ional supplement, feedstuff, food product, y supplement or food additive 35 comprising the composition according to any one of claims 1-3.